Modeling restoration of gefitinib efficacy by co‐administration of MET inhibitors in an EGFR inhibitor‐resistant NSCLC xenograft model: A tumor‐in‐host DEB‐based approach

MET receptor tyrosine kinase inhibitors (TKIs) can restore sensitivity to gefitinib, a TKI targeting epidermal growth factor receptor (EGFR), and promote apoptosis in non‐small cell lung cancer (NSCLC) models resistant to gefitinib treatment in vitro and in vivo. Several novel MET inhibitors are cur...

Descripción completa

Detalles Bibliográficos
Autores principales: Tosca, Elena M., Gauderat, Glenn, Fouliard, Sylvain, Burbridge, Mike, Chenel, Marylore, Magni, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592518/
https://www.ncbi.nlm.nih.gov/pubmed/34708556
http://dx.doi.org/10.1002/psp4.12710

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592518/
https://www.ncbi.nlm.nih.gov/pubmed/34708556
http://dx.doi.org/10.1002/psp4.12710

Ejemplares similares